Publications
414 results found
Lythgoe M, Dama P, Frampton AE, et al., 2023, Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: Updated safety data, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Kim JH, Kim SI, Park EY, et al., 2023, Impact of postoperative residual disease in patients with primary epithelial ovarian cancer in the era of maintenance therapies with targeted agents: A systematic review and meta-analysis., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Krell J, Frost S, Negroni C, et al., 2023, Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Chargari C, Tanderup K, Planchamp F, et al., 2023, ESGO/ESTRO quality indicators for radiation therapy of cervical cancer, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 33, Pages: 862-875, ISSN: 1048-891X
- Author Web Link
- Cite
- Citations: 2
Nelson G, Fotopoulou C, Taylor J, et al., 2023, Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges-2023 update, GYNECOLOGIC ONCOLOGY, Vol: 173, Pages: 58-67, ISSN: 0090-8258
- Author Web Link
- Cite
- Citations: 6
Reid I, Sharma A, Gogbashian A, et al., 2023, Germ cell cancer in pregnancy-Successfully treated with chemotherapy and surgery, GYNECOLOGIC ONCOLOGY REPORTS, Vol: 47, ISSN: 2352-5789
Chargari C, Tanderup K, Planchamp F, et al., 2023, ESGO/ESTRO quality indicators for radiation therapy of cervical cancer q, RADIOTHERAPY AND ONCOLOGY, Vol: 183, ISSN: 0167-8140
- Author Web Link
- Cite
- Citations: 1
Fotopoulou C, Khan T, Bracinik J, et al., 2023, Outcomes of Gynecologic Cancer Surgery During the COVID-19 Pandemic: An International, Multicenter, Prospective CovidSurg-Gynecologic Oncology Cancer Study, OBSTETRICAL & GYNECOLOGICAL SURVEY, Vol: 78, Pages: 277-278, ISSN: 0029-7828
Burns EM, Quyn A, Lexicon Collaboration of UKPEN and the ACPGBI Advanced Cancer subcommittee, 2023, The 'Pelvic exenteration lexicon': Creating a common language for complex pelvic cancer surgery., Colorectal Dis, Vol: 25, Pages: 888-896
AIM: Pelvic exenteration surgery is an umbrella term for a multitude of operative techniques for locally advanced and recurrent pelvic malignancy. Currently, there is heterogeneity in the operative description that limits the interpretation of patient outcome and collaboration between units through standardized data collection. Our study aims to develop a consensus lexicon to describe the operative components of extended and exenteration pelvic surgery. METHOD: This study adopted a mixed-methods approach using semi-structured interviews, questionnaires, focus groups and validation exercises involving pelvic exenteration experts from centres in the UK. Qualitative data were collected, and descriptive statistics are presented. RESULTS: We identified eight headings with 32 subheadings that encompass all components of the extent of the potential surgery. The lexicon was validated by 15 UK specialists. A 'high-complexity pelvic exenteration' was defined as encompassing 'conventional pelvic exenteration' with the extension of surgery to remove bony structures or the structures in the pelvic sidewall. Pelvic sidewall structures include major vessels, sciatic nerves and/or bone. Bony structures include the sacrum and/or pubic bones. CONCLUSION: This pelvic exenteration lexicon will permit classification of the surgical approach used that will improve data synthesis, allow more accurate activity recording for audit and ultimately improved outcomes for patients.
Hu Z, Cunnea P, Zhong Z, et al., 2023, Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><p>Supplementary Figures and Tables</p></jats:p>
Hu Z, Cunnea P, Zhong Z, et al., 2023, Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><p>Supplementary Figures and Tables</p></jats:p>
Hu Z, Cunnea P, Zhong Z, et al., 2023, Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><p>Table S2. The QuPath classification results for the immunohistochemistry of CAPS in SOC tissue microarrays.</p></jats:p>
Hu Z, Cunnea P, Zhong Z, et al., 2023, Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><div>AbstractPurpose:<p>Using RNA sequencing, we recently developed the 52-gene–based Oxford classifier of carcinoma of the ovary (Oxford Classic, OxC) for molecular stratification of serous ovarian cancers (SOCs) based on the molecular profiles of their cell of origin in the fallopian tube epithelium. Here, we developed a 52-gene NanoString panel for the OxC to test the robustness of the classifier.</p>Experimental Design:<p>We measured the expression of the 52 genes in an independent cohort of prospectively collected SOC samples (<i>n</i> = 150) from a homogenous cohort who were treated with maximal debulking surgery and chemotherapy. We performed data mining of published expression profiles of SOCs and validated the classifier results on tissue arrays comprising 137 SOCs.</p>Results:<p>We found evidence of profound nongenetic heterogeneity in SOCs. Approximately 20% of SOCs were classified as epithelial-to-mesenchymal transition–high (EMT-high) tumors, which were associated with poor survival. This was independent of established prognostic factors, such as tumor stage, tumor grade, and residual disease after surgery (HR, 3.3; <i>P</i> = 0.02). Mining expression data of 593 patients revealed a significant association between the EMT scores of tumors and the estimated fraction of alternatively activated macrophages (M2; <i>P</i> < 0.0001), suggesting a mechanistic link between immunosuppression and poor prognosis in EMT-high tumors.</p>Conclusions:<p>The OxC-defined EMT-high SOCs carry particularly poor prognosis independent of established clinical parameters. These tumors are associated with high frequency of immunosuppressive macrophages, suggesting a potential therapeutic target to improve clinical outcome.</p></div&
Hu Z, Cunnea P, Zhong Z, et al., 2023, Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><div>AbstractPurpose:<p>Using RNA sequencing, we recently developed the 52-gene–based Oxford classifier of carcinoma of the ovary (Oxford Classic, OxC) for molecular stratification of serous ovarian cancers (SOCs) based on the molecular profiles of their cell of origin in the fallopian tube epithelium. Here, we developed a 52-gene NanoString panel for the OxC to test the robustness of the classifier.</p>Experimental Design:<p>We measured the expression of the 52 genes in an independent cohort of prospectively collected SOC samples (<i>n</i> = 150) from a homogenous cohort who were treated with maximal debulking surgery and chemotherapy. We performed data mining of published expression profiles of SOCs and validated the classifier results on tissue arrays comprising 137 SOCs.</p>Results:<p>We found evidence of profound nongenetic heterogeneity in SOCs. Approximately 20% of SOCs were classified as epithelial-to-mesenchymal transition–high (EMT-high) tumors, which were associated with poor survival. This was independent of established prognostic factors, such as tumor stage, tumor grade, and residual disease after surgery (HR, 3.3; <i>P</i> = 0.02). Mining expression data of 593 patients revealed a significant association between the EMT scores of tumors and the estimated fraction of alternatively activated macrophages (M2; <i>P</i> < 0.0001), suggesting a mechanistic link between immunosuppression and poor prognosis in EMT-high tumors.</p>Conclusions:<p>The OxC-defined EMT-high SOCs carry particularly poor prognosis independent of established clinical parameters. These tumors are associated with high frequency of immunosuppressive macrophages, suggesting a potential therapeutic target to improve clinical outcome.</p></div&
Hu Z, Cunnea P, Zhong Z, et al., 2023, Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
<jats:p><p>Table S2. The QuPath classification results for the immunohistochemistry of CAPS in SOC tissue microarrays.</p></jats:p>
Fotopoulou C, 2023, Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon, GYNECOLOGIC ONCOLOGY, Vol: 170, Pages: A1-A3, ISSN: 0090-8258
Martinez A, Lecuru F, Bizzarri N, et al., 2023, PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, ISSN: 1048-891X
- Author Web Link
- Cite
- Citations: 2
Sundar S, Nordin A, Morrison J, et al., 2023, British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer, CANCERS, Vol: 15
Angeles MA, Boria F, Shushkevich AB, et al., 2023, Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 33, Pages: 12-18, ISSN: 1048-891X
Gomez-Hidalgo NR, Pletnev A, Razumova Z, et al., 2023, European Enhanced Recovery After Surgery (ERAS) gynecologic oncology survey: Status of ERAS protocol implementation across Europe, INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, Vol: 160, Pages: 306-312, ISSN: 0020-7292
- Author Web Link
- Cite
- Citations: 3
Strojna AN, Kacperczyk-Bartnik J, Angeles MA, et al., 2022, ENYGO-IJGC scientific writing and publication course: 2021 meeting summary, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1599-1605, ISSN: 1048-891X
Kim SI, Kim JH, Lee S, et al., 2022, Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis, GYNECOLOGIC ONCOLOGY, Vol: 167, Pages: 547-556, ISSN: 0090-8258
- Author Web Link
- Cite
- Citations: 5
Chiva L, Knapp P, Fotopoulou C, 2022, Perioperative ovarian cancer management: management of bowel related morbidity, prophylactic stoma formation, and stoma reversal, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1623-1625, ISSN: 1048-891X
Hasenburg A, Sehouli J, Fotopoulou C, 2022, Peri-operative ovarian cancer guidelines: psycho-oncology, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1626-1628, ISSN: 1048-891X
Fotopoulou C, Haidopoulos D, Trappe RU, 2022, Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1621-1622, ISSN: 1048-891X
Fotopoulou C, Khan T, Bracinik J, et al., 2022, OUTCOMES OF GYNAECOLOGICAL CANCER SURGERY DURING THE COVID-19 PANDEMIC: RESULTS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE COVIDSURGGYNAECOLOGICAL CANCER STUDY, Publisher: BMJ PUBLISHING GROUP, Pages: A10-A10, ISSN: 1048-891X
Yang Y, Li H, Fotopoulou C, et al., 2022, Toll-like receptor-targeted anti-tumor therapies: Advances and challenges, Frontiers in Immunology, Vol: 13, Pages: 1-37, ISSN: 1664-3224
Toll-like receptors (TLRs) are pattern recognition receptors, originally discovered to stimulate innate immune reactions against microbial infection. TLRs also play essential roles in bridging the innate and adaptive immune system, playing multiple roles in inflammation, autoimmune diseases, and cancer. Thanks to the immune stimulatory potential of TLRs, TLR-targeted strategies in cancer treatment have proved to be able to regulate the tumor microenvironment towards tumoricidal phenotypes. Quantities of pre-clinical studies and clinical trials using TLR-targeted strategies in treating cancer have been initiated, with some drugs already becoming part of standard care. Here we review the structure, ligand, signaling pathways, and expression of TLRs; we then provide an overview of the pre-clinical studies and an updated clinical trial watch targeting each TLR in cancer treatment; and finally, we discuss the challenges and prospects of TLR-targeted therapy.
Fotopoulou C, Khan T, Bracinik J, et al., 2022, Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, Vol: 227, ISSN: 0002-9378
- Author Web Link
- Cite
- Citations: 15
Lythgoe M, Mullish B, Frampton A, et al., 2022, ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY, Publisher: BMJ PUBLISHING GROUP, Pages: A659-A659
Taskiran C, Knapp P, Fotopoulou C, 2022, Perioperative ovarian cancer guidelines: prevention and management of upper abdominal complications, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1486-1487, ISSN: 1048-891X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.